IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IBRX is not a clean buy right now for a beginner long-term investor, even with a sizable $50,000-$100,000 budget. The stock has solid long-term commercial momentum, but the current setup is mixed: the technical trend is weak, options sentiment is bullish but not strong enough to override the chart, and the recent lawsuit headlines create event risk. Given the investor is impatient and unwilling to wait for an optimal entry, the best direct call is hold rather than buy.
Technically, IBRX is trading around 7.10 in pre-market, below the pivot level of 7.63 and only slightly above support at 6.931. The MACD histogram is negative and still expanding lower, which points to short-term downside pressure. RSI_6 at 37.52 is neutral-to-weak, and the moving averages are converging, suggesting the stock is not in a strong confirmed uptrend right now. The pattern-based forecast also suggests modest near-term weakness before improvement. Overall, the chart does not support an aggressive buy at this moment.
["Analyst coverage remains strongly positive, with BTIG initiating Buy and a $13 target.", "Piper Sandler raised its target to $12 and kept Overweight.", "H.C. Wainwright raised its target to $15 and kept Buy.", "2025/Q4 revenue jumped 406.95% YoY to 38.29M, showing strong commercial growth.", "ANKTIVA continues to drive major growth, with reported 700% YoY U.S. net revenue growth and EU expansion.", "International label expansion and new approvals provide real long-term commercial catalysts.", "Options data is bullish, with low put-call ratios showing call-heavy sentiment."]
["Multiple class action lawsuit headlines were filed on 2026-04-30 alleging securities fraud and overstating ANKTIVA performance.", "Net income remains deeply negative at -61.94M in the latest quarter.", "EPS was negative at -0.06 and worsened YoY.", "MACD remains bearish and deteriorating.", "Hedge fund and insider trading trends are neutral, showing no strong conviction buying.", "No AI Stock Picker or SwingMax signal is present today."]
In 2025/Q4, ImmunityBio posted very strong top-line growth, with revenue rising 406.95% YoY to 38.29M. The latest quarter season is 2025/Q4. However, profitability is still weak: net income was -61.94M and EPS was -0.06. Gross margin remains extremely high at 99%, but the company is still not profitable and earnings quality remains a concern. The main takeaway is rapid commercial growth, but continued losses.
Analysts have turned increasingly positive recently. BTIG initiated coverage with a Buy and $13 target on 2026-03-11, Piper Sandler raised its target to $12 from $7 and stayed Overweight on 2026-03-04, and H.C. Wainwright lifted its target to $15 from $10 and kept Buy on 2026-02-23. The Wall Street view is broadly bullish on long-term commercial potential, driven by ANKTIVA growth and international expansion. The pro case is strong revenue momentum and expanding market access; the con case is that the company is still loss-making and now faces lawsuit-related overhangs.
